Breaking Leprosy Transmission: India’s Challenge beyond Elimination

Why in News?

The National Leprosy Eradication Programme (NLEP) Annual Report 2025-26 highlights that despite India achieving national-level elimination as a public health problem in 2005, localised transmission remains rampant. 

Severe gaps against programme projections underscore the urgent need to overhaul the National Strategic Plan (NSP) and Roadmap for Leprosy 2023-27 to move from statistical elimination to interrupting transmission. 

Key Data (NLEP 2025-26 & WHO Metrics):

• Case Load: 91,783 new cases were detected nationwide, including 3832 children. Indian children accounted for nearly 46% of all global cases reported among children in 2025.
• National Prevalence Rate: Stood at 0.56 per 10,000 population (well below the elimination threshold of 1 per 10,000).
• District Performance: Only 148 districts were provisionally identified as having interrupted transmission (pending rigorous field verification), falling short of the projected 300 districts.
• The Projection Gap: Actual findings overshot the programme’s 2025-26 projections across key indicators:
  • Overall New Cases: Overshot by 41%
  • Childhood Incidence: Overshot by 91.6%
  • Grade-2 Disability (G2D) Rate: Overshot by 34%

What is Leprosy?

• Also known as Hansen’s disease, it is a chronic infectious disease caused primarily by the rod-shaped bacterium Mycobacterium leprae. It is classified by the WHO as a Neglected Tropical Disease (NTD).
• Transmission: Spreads via respiratory droplets from the nose and mouth during prolonged, close contact with an untreated individual. It is not transmitted via casual contact (e.g., shaking hands, hugging, or sharing food).
• Incubation Period: Highly variable, averaging 5 years, though symptoms can take up to 20 years or longer to manifest due to the slow replication of the pathogen.
• Pathology: It primarily targets the skin, peripheral nerves, mucosa of the upper respiratory tract, and the eyes. Classic clinical signs include pale or reddish skin patches with a distinct loss of sensation, muscle weakness, and tingling. Left untreated, it causes progressive, permanent nerve damage and physical deformities.
• Standard Treatment (MDT): Leprosy is entirely curable using Multidrug Therapy (MDT). It uses a combination of Rifampicin, Dapsone, and Clofazimine.
  • Paucibacillary (PB) cases: Treated for 6 months.
  • Multibacillary (MB) cases: Treated for 12 months.

Why does Transmission Continue?

• Elimination vs. Interruption of Transmission: India’s 2005 milestone defined elimination purely as a registered prevalence under 1 per 10,000 people. It did not mean zero transmission. Active childhood cases in India are a stark warning that community transmission is prevalent.
• Statistical Illusion of Shorter Regimens: Advanced MDT regimens successfully reduced the duration for which a patient remains on formal treatment registers. While this legally and statistically lowered the “prevalence rate” on paper, it did not stop the underlying pathogen transmission in unscreened populations.
• National Averages mask Regional Hotspots: The low national average (0.56/10,000) conceals severe hyper-endemic pockets. States like Chhattisgarh, Jharkhand, Odisha, and Maharashtra, alongside the UT of Chandigarh, remain above the elimination threshold. 
• Stigma-Diagnostic Delay Trap: Deep-rooted social stigma forces patients to hide symptoms. Concurrently, many clinical practitioners frequently misdiagnose early nerve involvement as a generic, benign skin condition. 

Current Institutional Interventions:

• National Leprosy Eradication Programme (NLEP): Launched in 1983 as a Centrally Sponsored Scheme under the National Health Mission (NHM). It institutionalises free diagnosis, MDT, disability prevention, and medical rehabilitation services across the public healthcare layer.
• National Strategic Plan (NSP) and Roadmap (2023-2027): A targeted strategy designed to fast-track the absolute interruption of leprosy transmission at the district level by 2027.
• Revised Three-Drug Regimen (Implemented April 1, 2025): To prevent drug resistance and strengthen clearance, India updated its clinical guidelines to administer the three-drug MDT combination (Rifampicin + Dapsone + Clofazimine) to both PB and MB cases. This added Clofazimine to the erstwhile two-drug PB regimen.
• Contact-Based Post-Exposure Prophylaxis (PEP): Active tracing is paired with the administration of Single-Dose Rifampicin (SDR-PEP) to eligible close contacts. In 2025-26, this prophylactic coverage reached an impressive 91.1% of the 16.9 lakh identified close contacts.

Technological and Grassroots Surveillance:

• Nikusth 2.0: A centralised digital platform utilised for the real-time recording, geolocated reporting, and long-term treatment follow-up of leprosy cases.
• Mass Field Mobilisation: In 2025-26, healthcare workers executed massive case-detection campaigns, screening over 70 crore people in high-endemic areas. Frontline ASHA workers flagged nearly 40 lakh suspected cases, of which 48,027 cases were clinically confirmed.
• Sparsh Leprosy Awareness Campaign: Nationwide community-level behavioural change communication drive aimed at dismantling misconceptions, reducing social exclusion, and promoting voluntary reporting.
• Antimicrobial Resistance (AMR) Surveillance: Targeted network to monitor and isolate M. leprae strains showing resistance to first-line MDT drugs.

The MIP Vaccine:

To accelerate elimination, the government is actively deliberating the strategic rollout of the Mycobacterium indicus pranii (MIP) Vaccine.

• An indigenous, killed-bacterial vaccine developed in India. It is derived from a non-pathogenic, soil-borne mycobacterium that shares safe structural antigens with M. leprae.
• Mechanism of Action: It boosts host cell-mediated immunity (CMI). When deployed as an adjunct immunotherapy alongside standard MDT, it significantly accelerates bacterial clearance in highly infectious Multibacillary (MB) patients. It has also shown efficacy in providing long-term preventive protection to close contacts.
• The vaccine is currently under deliberation for targeted use in highly infectious cohorts to clear persistent reservoirs. It is not yet a nationwide open rollout.

Way Forward:

• Shift Performance Metrics: Move focus from deceptive “prevalence rates” to direct transmission indicators like childhood incidence trends, detection timelines, and diagnostic delays.
• Incentivise High Detection: Resist relaxing screenings to meet artificial deadlines; treat initial spikes in case counts as a surveillance success rather than a policy failure.
• Hyper-Local Resource Mapping: Transition from broad state-level funding to block-level operational plans that concentrate intensive contact tracing and SDR-PEP in known endemic pockets.
• Synergise Pediatric Care: Break NLEP silos by integrating leprosy screening directly with school health checkups and pediatric networks like the Rashtriya Bal Swasthya Karyakram (RBSK) to tackle high child case rates.
• Provide Holistic Post-Cure Care: Extend interventions beyond bacterial clearance to include long-term nerve monitoring, reconstructive surgeries, and psychosocial rehabilitation.

India’s next milestone requires sustained interruption of transmission, supported by early diagnosis, contact-based prevention and dignified care. 

Practice MCQ: 

Q. With reference to Leprosy (Hansen’s disease) and India’s public health policies, consider the following statements:

1. Leprosy is a bacterial disease that primarily affects the skin and peripheral nerves.

2. Under the updated National Leprosy Eradication Programme (NLEP) guidelines, a uniform three-drug multidrug therapy (MDT) regimen is now administered to both Paucibacillary (PB) and Multibacillary (MB) cases.

Which of the statements given above are correct?

(a) 1 only

(b) 2 only

(c) Both 1 and 2

(d) Neither 1 nor 2 

Answer: (c)